Showing results (71-80 of 109) with videos related to
Sort By:
Pageof 11
Lung Cancer (Amsterdam, Netherlands)|November 19, 2013
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerKeiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, et al.Anticancer Research|January 1, 2015
FOXD1 expression is associated with poor prognosis in non-small cell lung cancerSohei Nakayama, Kenzo Soejima, Hiroyuki Yasuda, et al.Japanese Journal of Clinical Oncology|January 24, 2015
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancerShinnosuke Ikemura, Katsuhiko Naoki, Hiroyuki Yasuda, et al.Oncotarget|October 31, 2015
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerToshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, et al.Clinical Lung Cancer|June 9, 2022
Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysisTakahiro Fukushima, Yoshitaka Oyamada, Shinnosuke Ikemura, et al.European Journal of Cancer (Oxford, England : 1990)|March 11, 2023
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)Atsushi Nakamura, Ou Yamaguchi, Keita Mori, et al.Journal of Clinical Medicine|January 8, 2025
Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter AnalysisMasahiko Okada, Keiko Ohgino, Kohei Horiuchi, et al.Scientific Reports|February 15, 2024
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051Keita Miura, Ou Yamaguchi, Keita Mori, et al.Clinical Lung Cancer|February 6, 2018
Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter AnalysisKeigo Kobayashi, Ichiro Nakachi, Katsuhiko Naoki, et al.JTO Clinical and Research Reports|June 30, 2022
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort StudyHayato Kawachi, Motohiro Tamiya, Yoshihiko Taniguchi, et al.Pageof 11